跳至主要内容
临床试验/NL-OMON24025
NL-OMON24025已完成不适用

A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia. A collaborative study of the Interfant network

Princess Maxima Center for Pediatric Oncology0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • In order to be eligible to participate in this study, a patient must meet all of the following criteria:
  • 1. Patients must be treated according to Interfant-06 backbone

排除标准

  • A potential patient who meets any of the following criteria will be excluded from participation in this study:
  • 1. Biphenotypic ALL

研究者

发起方
Princess Maxima Center for Pediatric Oncology

相似试验

Blinatumomab in infant A | 临床试验